Sign In
Buy PLX
$1.96
-0.0300 (-1.51%)
At Close: Jun 03, 2026
Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript
11:50am, Wednesday, 13'th May 2026
Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
06:50am, Wednesday, 13'th May 2026
Company to host conference call and webcast today at 8:00 a.m. EDT Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen;
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
06:50am, Wednesday, 06'th May 2026
Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, May 6, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on t
Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance
02:42pm, Tuesday, 24'th Mar 2026
Protalix BioTherapeutics reported weaker FY25 results but issued robust FY26 revenue guidance of $78–83 million, well above consensus. PLX's growth thesis centers on Elfabrio's EU approval and once-
Americans are richer in shares, Europeans in bricks – and that matters now
10:11am, Thursday, 19'th Mar 2026
American and European households may be growing wealthier at a similar pace, but the composition of that wealth is strikingly different, and those...
Tesla targets December 2026 for next-generation AI6 chip tape-out
08:39am, Thursday, 19'th Mar 2026
Tesla Inc (NASDAQ:TSLA) CEO Elon Musk on Thursday shared an update on the company’s semiconductor plans, indicating that the firm may “tape out” its...
Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript
10:12am, Wednesday, 18'th Mar 2026
Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
09:07am, Wednesday, 18'th Mar 2026
Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined recent regulatory, clinical and commercial developments, including a new European approval for its
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
06:50am, Wednesday, 18'th Mar 2026
Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio® in adults living with Fabry diseas
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
05:02am, Wednesday, 18'th Mar 2026
Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined recent regulatory, clinical and commercial...
Pennon shares rise despite profit warning as storm costs and sewage penalties bite
05:43am, Tuesday, 10'th Mar 2026
Shares in Pennon Group PLC (LSE:PNN, OTC:PEGRY) rose 3.4% to 553.5p on Tueaday morning despite the owner of South West Water saying full-year profitability...
Physiomics shares fall 27% after discounted share placing
05:23am, Tuesday, 10'th Mar 2026
AIM modelling company raises £450,000 at a steep discount, betting that investment in growth will justify near-term pain for shareholders Shares in...
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
09:05am, Monday, 09'th Mar 2026
Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) announced that the European Commission has approved a new dosing regimen for pegunigalsidase alfa for adults with Fabry disease who are stable on en
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
06:40am, Monday, 09'th Mar 2026
Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) announced that the European Commission has approved a new dosing regimen for pegunigalsidase alfa for...
Ticketmaster owner Live Nation reaches antitrust settlement with US Justice Department
06:29am, Monday, 09'th Mar 2026
The US Justice Department has reportedly reached a settlement with Ticketmaster and its parent company, Live Nation Entertainment Inc (NYSE:LYV), resolving...
